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A rapid and sensitive ultra performance liquid chromatography–tandem mass spectrometry (UPLC–MS/
MS) method is described for determination of letrozole in human plasma. Following solid phase ex-
traction (SPE) of letrozole and letrozole-d4 on Orochem DVB-LP cartridges, chromatography was per-
formed on Acquity UPLC BEH C18 (50 mm2.1 mm, 1.7 mm) column using methanol-0.1% formic acid in
water (85:15, v/v) as the mobile phase. Detection was carried out on a triple quadrupole mass spec-
trometer with an electrospray source, operated under positive ionization mode. Quantitation of letrozole
and letrozole-d4 was done using multiple reaction monitoring (MRM) following the transitions at m/z
286.2-217.0 and m/z 290.2-221.0, respectively. The calibration plots were linear through the con-
centration range of 0.10–100 ng/mL (r2Z0.9990) using 100 mL human plasma. The extraction recovery of
letrozole ranged from 94.3% to 96.2% and the intra-batch and inter-batch precision was r5.2%. The
method was successfully applied to a bioequivalence study of letrozole after oral administration of
2.5 mg tablet formulation to 16 healthy postmenopausal Indian women. The assay reproducibility was
also established through incurred sample reanalysis (ISR) of 74 subject samples.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Letrozole (LTZ) is a third-generation, potent and selective non-
steroidal aromatase inhibitor. It is approved for anti-hormonal
therapy in postmenopausal women having estrogen receptor po-
sitive breast cancer. Aromatases (cytochrome P-450 [CYP] 19) are
enzymes that convert adrenal androgens into estrogens in the
peripheral tissues, which are responsible for the promotion and
progression of breast cancer in postmenopausal women. LTZ ef-
fectively suppresses the production of estrogen by preventing the
aromatase enzyme from producing estrogens through competitive
binding to the heme moiety of cytochrome P-450 subunit [1,2].
LTZ is rapidly and completely absorbed after oral administra-
tion with mean absolute bioavailability of 99.9%. It is weakly
bound to proteins (60%), primarily to albumin and has 1.9 L/kgon and hosting by Elsevier B.V. Th
University.
. Sanyal).volume of distribution at steady state. It is metabolized by
cytochrome P450 isoenzymes (CYP 3A4 and CYP 2A6) into a
pharmacologically inactive carbinol metabolite, which further
undergoes glucuronide conjugation [1,2]. Approximately 90% of
LTZ is recovered in urine, with a major part of about 75% corre-
sponding to the glucuronide conjugate of the carbinol metabolite.
The terminal elimination half-life of LTZ is about two days [2].
However, due to its low therapeutic dose (2.5 mg) and wide dis-
tribution in tissues, the plasma concentration of LTZ is rather low.
Thus, it is essential to establish a reliable, selective and sensitive
analytical method for the quantitation of LTZ, especially for phar-
macokinetic applications.
Several methods are reported for the determination of LTZ as a
single analyte [3–12], together with its inactive metabolites [13,14]
and with other drugs like tamoxifen and anastrozole [15] in dif-
ferent biological matrices. Mainly liquid chromatography with UV
[4,5,12], ﬂuorescence [3,14] or mass spectrometry [6–11,13,15]
detection has been used for the quantiﬁcation of LTZ in various
matrices like human urine, rat plasma and human plasma. All
previous methods based on liquid chromatography with massis is an open access article under the CC BY-NC-ND license
Table 1.
Comparative summary of liquid chromatography–tandem mass spectrometry methods developed for letrozole in human plasma.
Sr.
No.
Linear range
(ng/mL)
Plasma
volume
(mL)
Extraction procedure;
internal standard
Mean
recovery
(%)
Chromatographic
run time (min);
retention time
(min)
Application; Incurred sample reanalysis Ref.
1 0.20–100 250 LLE with methyl tert-butyl ether;
LTZ-d4
65.7 3.0; 1.25 Pharmacokinetic study with 2.5 mg LTZ in 72
healthy volunteers under fasting & fed condition; –
[7]
2 0.40–50 100 PP with methanol-water and
acetonitrile; LTZ-d4
90.5 4.0; 2.7 Clinical pharmacokinetic study with 2.5 mg LTZ in
20 healthy, post-menopausal Chinese women;
% change within 20%
[8]
3 0.25–100 500 SPE on SOLA cartridges;
olanzapine
87.1 3.0; 2.043 Pharmacokinetic study with 2.5 mg LTZ in 32 healthy,
post-menopausal women; –
[9]
4 1.0–60 50 PP with methanol; anastrozole – 5.5; 3.81 Analysis of samples from patients treated with
2.5 mg/day LTZ; –
[10]
5a 5.7–428 150 SPE on BondElut C18
96-well plates; LTZ-d4
98.5 4.75; 3.86 Quantiﬁcation of LTZ and its metabolites in the
plasma samples of 20 post-menopausal patients
with early breast cancer receiving a daily dose of
2.5 mg LTZ; –
[14]
6b 10–300 1000 SPE on Strata X-C; bunitrolol 49.0 16; 8.0 Analysis of plasma samples of 310 breast cancer
patients undergoing anti-estrogen therapy; –
[15]
7c 0.10–100 100 SPE on Orochem DVB-LP
cartridge; LTZ-d4
95.5 2.0; 1.21 Bioequivalence study with 2.5 mg LTZ in
16 healthy post-menopausal Indian women; % change
within 716%
PM
cLTZ: letrozole; PP: protein precipitation; LLE: liquid-liquid extraction; SPE: solid phase extraction; PM: present method.
a Together with its inactive metabolites, carbinol and carbinol glucuronide;
b Along with tamoxifen and anastrozole;
c UPLC–MS/MS method;
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and chromatographic analysis time ranging from 3.0 to 16.0 min.
The salient features of reported liquid chromatography–tandem
mass spectrometry (LC–MS/MS) methods developed for LTZ in
human plasma are summarized in Table 1.
Thus so far, there is only one report on the use of
ultra-performance liquid chromatography–tandem mass spectro-
metry (UPLC–MS/MS) for the determination of letrozole in rat
plasma. The linear concentration range was established from 2.0 to
2000 ng/mL using acetonitrile as protein precipitant for sample
preparation with recovery of 77.9%–79.5%. However, there are no
UPLC based methods for the determination of LTZ in human
plasma. Herein we describe development and validation of a
sensitive, selective and fast analytical method for quantiﬁcation of
LTZ in human plasma by UPLC–MS/MS using a deuterated internal
standard (LTZ-d4). The method presents an efﬁcient extraction
procedure based on solid phase extraction (SPE) with minimal
matrix interference. The proposed method was successfully ap-
plied to support a bioequivalence study of 2.5 mg letrozole tablet
formulation in 16 healthy postmenopausal Indian women under
fasting condition.2. Experimental
2.1. Chemicals and materials
The details of reference standards, their purity and other ma-
terials used in the study are given in Appendix A – Supplementary
data.
2.2. Liquid chromatographic and mass spectrometric conditions
A Waters Acquity UPLC system (MA, USA) consisting of binary
solvent manager, sample manager and column manager was used
to set the reversed-phase liquid chromatographic conditions. The
analysis of LTZ was performed on Waters Acquity UPLC BEH C18
(50 mm2.1 mm, 1.7 mm) column and maintained at 35 °C in acolumn oven. The mobile phase consisted of methanol-0.1% formic
acid in water (85:15, v/v). The ﬂow rate of the mobile phase was
kept at 0.300 mL/min. Ionization and detection of LTZ and internal
standard (IS) was carried out on Waters Quattro Premier XE triple
quadrupole mass spectrometer (MS; Milford, MA, USA), equipped
with electro spray ionization (ESI) source and operated in the
positive ionization mode. The source-dependent and compound-
dependent parameters optimized for LTZ and LTZ-d4 are presented
in Supplementary Table 1. Quadrupole 1 and 3 were maintained at
unit mass resolution and MassLynx software version 4.1 was used
to control all parameters of UPLC and MS.
2.3. Standard stock, calibration standards and quality control
samples
Calibration standards (CSs) were made at 0.10, 0.20, 0.50, 1.00,
2.00, 5.00, 10.0, 20.0, 50.0, and 100 ng/mL concentrations. Quality
control (QC) samples were prepared at 80.0 ng/mL (HQC, high
quality control), 40.0/15.0 ng/mL (MQC-1/2, medium quality con-
trol), 0.30 ng/mL (LQC, low quality control) and 0.10 ng/mL (LLOQ
QC, lower limit of quantiﬁcation quality control). The details of
solution preparation are provided in Appendix A – Supplementary
data.
2.4. Plasma sample extraction
Prior to analysis, all frozen subject samples, CSs and QC samples
were thawed and allowed to equilibrate at room temperature for
30 min. To an aliquot of 100 mL of spiked plasma sample, 50 mL of
IS solution and 300 mL of 0.1 M HCl in water were added and
vortex-mixed for 20 s. The samples were then centrifuged at
3200g for 5 min at 10 °C and loaded on Orochem DVB-LP (30 mg,
1 cc) extraction cartridges, which were preconditioned with
1.0 mL of methanol, followed by 1.0 mL of water. Washing of
samples was done with 21 mL of water. Elution of LTZ and LTZ-
d4 was completed using 20.5 mL of methanol into pre-labeled
vials. The eluates were evaporated to dryness under gentle stream
of nitrogen (20 psi) at 40 °C. The dried samples were reconstituted
Table 2.
Extraction recovery for letrozole and letrozole-d4.
QC level Letrozole Letrozole-d4
Area response (n¼6) Extraction recovery (%) Area response (n¼6) Extraction recovery (%)
Pre-extraction spiking Post-extraction spiking Pre-extraction spiking Post-extraction spiking
LQC 1246 1302 95.7 207,349 216,892 95.6
MQC-2 63,247 65,746 96.2 210,341 217,294 96.8
MQC-1 168,144 178,307 94.3 214,493 222,272 96.5
HQC 336,457 351,943 95.6 211,539 220,583 95.9
Extraction recovery: pre-extraction spiking/post-extraction spiking.
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was used for injection in the chromatographic system.
2.5. Assay validation
The bioanalytical method validation was performed as per the
United States Food and Drug Administration (USFDA) guidance
[16] and was similar to the one described in our previous report
[17]. Details of validation procedure and acceptance criteria are
given in Appendix A – Supplementary data.
2.6. Application of the method and incurred sample reanalysis (ISR)
A bioequivalence study was conducted with a single oral
dose of a test (2.5 mg letrozole tablets from a Generic Company,
India) and a reference (FEMARAs, 2.5 mg letrozole tablets from
Novartis Pharmaceutical Corporation, East Hanover, NJ 07936-
1080, USA) formulation in 16 healthy postmenopausal Indian
women under fasting. The study was conducted as per Inter-
national Conference on Harmonization, E6 Good Clinical Prac-
tice guidelines [18]. ISR was performed as reported previously
[19]. The details of both the experiments are provided in Ap-
pendix A – Supplementary data.3. Results and discussion
3.1. UPLC–MS/MS method development
To attain optimal analytical performance for the assay, MS
settings, sample clean-up and UPLC conditions were suitably in-
vestigated to achieve the desired sensitivity and short analysis
time. A standard solution (1000 ng/mL) of LTZ and LTZ-d4 was
directly infused into the MS using ESI as the ionization source. The
mass spectrometer was tuned in both positive and negative ioni-
zation modes to obtain consistent and abundant product ions in
the mass range of 100–340 amu, based on previous studies [6,7,9–
11]. Due to the presence of tertiary nitrogen groups in LTZ the
response in the positive ionization mode was greater than that in
the negative mode. The characteristic protonated precursor ions
for LTZ and LTZ-d4 were observed at m/z 286.2 and m/z 290.2
respectively in the Q1 spectra. The most abundant and consistent
product ion was found at m/z 217.0 and 221.0 for LTZ and LTZ-d4,
respectively, which can be attributed to the loss of triazole moiety
from their precursor ions (Supplementary Figs. 1 and 2). For
quantiﬁcation of LTZ and LTZ-d4, a dwell time of 150 ms was
adequate to generate sufﬁcient data points.
To establish a linear concentration range from 0.1 to 100 ng/mL,
it was essential to optimize an efﬁcient extraction protocol to
obtain quantitative and precise recovery of LTZ and LTZ-d4 with
minimal matrix effect. As all three conventional extractionmethodologies, namely protein precipitation (PP) [8,10], liquid-li-
quid extraction (LLE) [7,12] and SPE [6,9,11], have been used pre-
viously, a systematic study was undertaken to optimize the best
extraction conditions with all three approaches. As the PP has the
advantage of simplicity and speed of analysis, the initial attempts
were done with methanol and acetonitrile as protein precipitants.
However, this technique did not provide cleaner extracts which
were apparent from strong matrix interferences and poor recovery
especially at LLOQ and LQC concentration levels. A similar ob-
servation was also reported in a previous study [12]. Further, LLE
was tested using methyl tert-butyl ether, dichloromethane, n-
hexane and ethyl acetate as single solvents and also as binary
mixtures in different proportions. In majority of the extraction
trials the recovery was in the range of 64 %–73 %, but there was
some inconsistency at lower concentration levels. As a result, SPE
was explored to obtain cleaner extract for better signal intensity
and recovery of LTZ. In this experiment two different extraction
cartridges, Orochem DVB-LP and Lichrosep DVB HL, were tested.
With both the cartridges extraction was performed under acidic as
well as basic conditions. However, the response obtained under
alkaline conditions was too low compared to that under acidic
conditions. Additionally, the mean recovery found was somewhat
less with Lichrosep DVB HL (85.7%) compared to Orochem DVB-LP.
Nevertheless, superior results were obtained under acidic condi-
tions (0.1 M HCl) on Orochem DVB-LP cartridges and hence they
were chosen in the present work. The mean extraction recovery of
LTZ and LTZ-d4 was 95.5% and 96.2%, respectively, which was
highly consistent at all QC levels (Table 2).
Chromatographic conditions were optimized to obtain high
sensitivity and sample throughput. Different mobile phase com-
positions and mobile phase additives were explored to achieve
optimal peak shape, adequate retention and response on UPLC
BEH C18 (50 mm2.1 mm, 1.7 mm). The mobile phase systems
consisting of acetonitrile–water and methanol–water with am-
monium acetate/formate buffers and formic acid/acetic acid in
different volume ratios were tested. A summary of various trials
conducted with different mobile phases on this column is pre-
sented in Table 3. Methanol was selected as the organic modiﬁer
since it provided a better chromatographic peak shape and re-
sponse for LTZ compared to acetonitrile. Further, formic acid rather
than acetic acid or the acidic buffers assisted better to accomplish
good peak shape and response in the positive mode. To set the
optimum mobile phase conditions, the ratio of the organic diluent
varied from 60% to 90% and the concentration of formic acid was
tested in the range of 0.05%–0.2%. The best chromatographic
conditions as a function of analyte peak intensity, peak shape,
adequate retention and analysis were obtained using methanol-
0.1% formic acid in water (85:15, v/v) as the mobile phase under
isocratic elution. The retention time for LTZ and LTZ-d4 was 1.21
and 1.20 min, respectively within 2.0 min at a ﬂow rate of 0.3 mL/
min, ensuring high throughput of the method. The reproducibility
Table 3.
Results of chromatographic trials on Waters Acquity UPLC BEH C18 (50 mm2.1 mm, 1.7 mm) analytical column.
Sr. No. Mobile phase, ﬂow rate (0.300 mL/min) Retention time for LTZ
(min)
Observation
1 MeOH:10.0 mM AF buffer (80:20, v/v) 2.37 Peak shape was slightly broad and response was also low, run time 3.5 min
2 ACN:10.0 mM AF buffer (80:20, v/v) 2.45 Peak shape was slightly broad and response was also low, run time 3.5 min
3 0.1% FA in water: 0.1% FA in MeOH (20:80, v/v) 2.22 Peak shape and response was better compared to AF buffer (Sr. No. 1 and 2),
run time 3.5 min
4 0.1% FA in water: MeOH-ACN (50:50, v/v) (20:80,
v/v)
2.34 Peak shape was good but the response was somewhat unacceptable, run time
3.5 min
5 MeOH:0.1% FA in water (70:30, v/v) 2.06 Adequate retention, response was acceptable but the peak was slightly broad
6 ACN:0.1% FA in water (70:30, v/v) 2.04 Adequate retention, response was acceptable but the peak was broad
7 MeOH:0.1% FA in water (80:20, v/v) 1.27 Slight peak tailing, adequate response and retention, run time 2.0 min
8 ACN:0.1% FA in water (80:20, v/v) 1.28 Adequate retention, better response but the peak shape was slightly broad,
run time 2.0 min
9 MeOH:0.1% FA in water (85:15, v/v) 1.21 Good peak shape, adequate response, adequate retention and short analysis
time (2.0 min)
ACN: acetonitrile; MeOH: methanol; AF: ammonium formate; FA: formic acid; LTZ: letrozole.
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was r0.6% for a minimum of 100 injections on the same column.
Deuterated internal standard, LTZ-d4 used in the present work
was useful in maintaining overall accuracy and precision of the
data. The speciﬁcity of the method was evident from the re-
presentative multiple reaction monitoring (MRM) ion chromato-
grams of blank plasma, LLOQ sample and a subject sample in Fig. 1.
No signiﬁcant interference in the drug free blank plasma samples
was observed at the retention time of the analyte. The post column
infusion experiment showed no interfering signals at the retention
time of the analyte and IS from endogenous plasma components
(Supplementary Fig. 3). Likewise, none of the medications com-
monly used by healthy subjects interfered at the retention time of
LTZ. Matrix effect, expressed as IS-normalized matrix factors (MFs)
was found in the range of 0.981–1.032, indicating minimal ion
suppression/enhancement (Table 4). The relative matrix effect
calculated in terms of % CV value with ten different plasma sources
was 2.60, which is within the acceptance criteria of r3.0% using
labeled IS (Supplementary Table 2).
3.2. Assay validation
The precision (% CV) values for system suitability test varied
from 0.12% to 0.32% for the retention time and 0.45% to 0.78% for
the area response of LTZ and LTZ-d4. The signal-to-noise (S/N)
ratio for system performance was Z24. The auto-sampler carry-
over experiment showed minimal carryover of analyte (r0.03% of
LLOQ area) in the extracted blank sample injected immediately
after ULOQ sample.
The calibration curves showed good linearity (r2Z0.9990) in
the studied concentration range of 0.10–100 ng/mL for LTZ. The
mean linear equation for calibration curve concentrations was y¼
(1.0148xþ0.0214)x(0.122370.2435). The accuracy (%) and pre-
cision (% CV) values for CSs ranged from 98.2% to 102.0% and 1.76%
to 5.46%, respectively. The LLOQ (0.10 ng/mL) was measured at an
S/N Z24.
The intra-batch precision (% CV) varied from 1.5% to 4.5% while
the accuracy was within 96.7%–102.5%. For the inter-batch ex-
periments, the precision (% CV) ranged from 2.4% to 5.2% and the
accuracy was between 96.3% and 102.0% (Supplementary Table 3).
The stability of LTZ was thoroughly evaluated in stock solutions
prepared in methanol and in plasma samples under different
storage conditions. Stock solutions of LTZ and LTZ-d4 kept for
short-term stability remained stable at room temperature up to
7 h, and for long-term stability (a minimum of 7 days) at re-
frigerated temperature of 5 °C with % change r1.8 for both the
experiments. The detailed results of LTZ stability in plasma areshown in Supplementary Table 4. Further, the % change for whole
blood sample stability was less than 4.2% when compared with
freshly spiked blood samples at the LQC and HQC levels.
The precision (% CV) and accuracy values on different columns
and from analysts for method ruggedness ranged from 0.72% to
1.15% and 96.8% to 101.5%, respectively, across ﬁve QC levels. The
precision values for dilution integrity of 1/5th and 1/10th dilution
were 1.5% and 2.1%, respectively, while the corresponding accuracy
was 97.4% and 102.6%, respectively.
3.3. Application to a bioequivalence study and ISR results
The proposed assay was successfully applied to a pharmaco-
kinetic study in 16 healthy postmenopausal Indian women. The
mean concentration (Cmax) in plasma (41.2279.51 ng/mL) for LTZ
was attained at 1.5370.75 h (Tmax) with a half-life (t1/2) of
40.2071.80 h. The area under the plasma concentration–time
curve from time zero to the last measurable time point (AUC0–t)
and area under the plasma concentration time curve from time
zero to inﬁnity (AUC0-inf) for LTZ were 2220.47189.3 and 2181.27
210.7 h ng/mL, respectively. The mean plasma concentration and
time proﬁle for 2.5 mg test and reference formulation of LTZ is
shown in Fig. 2. It has been reported that the efﬁcacy of LTZ is not
consistent and that there is some inter-individual variability. The
mean Cmax, Tmax and t1/2 values obtained for LTZ in the present
work were comparable with a similar study involving 20 healthy
Portuguese postmenopausal female volunteers [6]. However,
AUC0–240 and AUC0-inf values were much higher compared to those
in Portuguese subjects for identical dose strength. On the contrary,
these two parameters were in good agreement with the Chinese
subjects but showed signiﬁcant difference in the t1/2 values
(69.0 h) [8]. This difference can be attributed to several factors
including race of subjects, type of food and others. Nevertheless,
the mean log-transformed ratios of the Cmax, AUC0–240 and
AUC0-inf and their 90% conﬁdence intervals were between 95%
and 109%, which is within the deﬁned bioequivalence range of
80%–125% (Supplementary Table 5). The study data was also
authenticated through ISR study by reanalysis of 74 incurred
samples. The results showed % change within 716%, which is
within the acceptance criterion of 720% and thus demon-
strated excellent reproducibility of the proposed method (Sup-
plementary Fig. 4).
4. Conclusion
A selective, simple and rapid UPLC–MS/MS method was devel-
oped and fully validated for the quantiﬁcation of LTZ in human
Fig. 1. MRM ion chromatograms of (A) double blank plasma (without IS), (B) blank plasma with letrozole-d4 (IS), (C) letrozole at LLOQ and IS, and (D) subject sample at Cmax
after administration of 2.5 mg dose of letrozole and IS.
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sharp peak shapes, enhanced peak capacity and speed of analysis
without compromising sensitivity. LTZ and its deuterated IS were
rapidly eluted in a run time of 2.0 min per sample and thus the
method has the shortest analysis time for the determination of LTZ.
In comparisonwith other reports, the proposed method was provedto be highly sensitive with LLOQ of 0.10 ng/mL, using small plasma
volume for processing. Additionally, the method is speciﬁc and is
unaffected by any endogenous matrix components. Further, the
method was successfully applied to a pharmacokinetic study of
2.5 mg LTZ in healthy postmenopausal women and the reproduci-
bility of the assay was demonstrated by incurred sample reanalysis.
Table 4.
Matrix factors for letrozole and letrozole-d4 (IS).
QC level Letrozole Letrozole-d4
Area response (n¼6) Matrix factor Area response (n¼6) Matrix factor IS-normalized matrix
factor
Post-extraction
spiking
Neat samples in mobile
phase
Post-extraction
spiking
Neat samples in mobile
phase
LQC 1302 1305 0.998 216,892 224,281 0.967 1.032
MQC-2 65,746 64,457 1.020 217,294 208,986 1.040 0.981
MQC-1 178,307 178,844 0.997 222,272 225,839 0.984 1.013
HQC 351,943 361,709 0.973 220,583 225,344 0.979 0.994
Matrix factor: post-extraction spiking/neat samples in mobile phase.
Fig. 2. Mean plasma concentration–time proﬁle of letrozole after oral adminis-
tration of 2.5 mg (test and reference) tablet formulation to 16 healthy post-
menopausal Indian women.
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